MedTrace Logo

Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer

NCT03797248 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2019-09-17

No results posted yet for this study

Summary

This 2-year trial is intended to be used to study breast cancer patients through forward-looking generation design through collaboration between Chinese and Western medical teams. The whole study consists of 2 stages, stage I comprises a cross-sectional study-baseline and stage II is a cohort for outcome evaluation and follow-up study across a 3-year period. To provide an empirical basis for combined TCM treatment in the Breast Cancer Research Team and to publish that as a reference for future TCM and Western medicine in integrative cancer treatment.

Conditions

Interventions

COMBINATION_PRODUCT

Chinese herbal medicine

All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chien-Ting Liu, MD · Division of Oncology, Department of Internal Medicine

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-12
Primary Completion
2020-10-24
Completion
2020-10-24

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03797248 on ClinicalTrials.gov